NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...

The Edinburgh-based ceramics expert, 38, reflected on her health and 'how she's feeling about things' in a candid new article ...

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...